Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

© ABCDstock - © ABCDstock - stock.adobe.com

Beyond Patient Centricity: What Rare Disease Research Gets Right

BySylvain Berthelot

September 4th 2026

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

ByAbigail Dirks, MS,Sylviane de Viron,Andy Studna, Senior Editor

September 4th 2026

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

ByAndy Studna, Senior Editor

September 4th 2026

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

ByAndy Studna, Senior Editor

September 3rd 2026

Why Time Savings Is the Largest Driver of RBQM's Financial Value

ByAbigail Dirks, MS,Sylviane de Viron,Andy Studna, Senior Editor

September 3rd 2026

Letters to the Editor

Articles in this issue

Related Content

Beyond Patient Centricity: What Rare Disease Research Gets Right

The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness

ACT Brief: Time Savings as RBQM Value Driver, FDA Tightens Foreign Trial Oversight, and Trusted Research Environments Versus Flat Files

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

Why Time Savings Is the Largest Driver of RBQM's Financial Value

Trending on Applied Clinical Trials Online

FDA Reaffirms GCP Standards Amid Growing Concerns Over Foreign Clinical Trial Data

Beyond Patient Centricity: What Rare Disease Research Gets Right

Fortrea to Acquire Worldwide Clinical Trials' Early Phase Services Division in $45 Million Deal

ACT Brief: Human Readiness as Operational Foundation, Early Phase Capacity Consolidation, and AI-Driven Patient Matching Scale

AI Moves Patient Recruitment from Trial Bottleneck to Competitive Edge: A 2026 Perspective